Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc and/or Favipiravir in Severe Non-critical COVID-19
NCT04475991Phase 2Terminated
- Sponsor
- Hospital General de México "Dr. Eduardo Liceaga"
- Start
- Jul 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of maraviroc, favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Hospital General de México "Dr. Eduardo Liceaga". Started Jul 2021; status: terminated.
02
Drugs
maravirocfavipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04475991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475991.